Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

45 results about "Anti-angiogenesis agent" patented technology

An anticancer sustained releasing agent

Disclosed is an anti-cancer slow release agent comprising slow release microspheres and dissolvent, wherein the slow release microspheres include slow release auxiliary materials, anti-angiogenesis agent and / or proteolytic enzyme, the dissolvent comprises suspension adjuvant. The anti-angiogenesis agent is selected from gefinitib, erlotinib, lapatinib, pelitinib, endostatin, imatinib, smasnib, avastin, sorafenib, sunitinib, oersted or panitoma, the proteolytic enzyme is selected from collagenase, hyaluronidase, relaxin and thrombase or the combination of them, the slow release auxiliary materials are selected from Polifeprosan, sebacylic acid copolymer, EVAc, polylactic acid and their mixture of copolymer, the viscosity of the suspension adjuvant is 100-3000cp (at 25-30 deg C), and is selected from sodium carboxymethylcellulose. The agent can also be prepared into implanting agent for injection or placement in or around tumor with the effects of selectively increasing local concentration, lowering general reaction of the drugs, suppressing growth of tumor cells and blood vessel, and improving the treatment effect of the non-operative treatment methods such as chemotherapy.
Owner:SHANDONG LANJIN PHARMA +1

Sesterterpene compound and preparation method and application thereof

The invention discloses a sesterterpene compound 1-34 and a medicinal composition taking the compound as an active ingredient. A preparation method of the sesterterpene compound 1-34 comprises the following steps of: performing direct cold soaking or thermal reflux extraction on leaves or flowers or stems of labiatae tripterygium hypoglaucum plant with an organic solvent, i.e., petroleum ether or n-hexane or cyclohexane or chloroform or acetone or methanol or ethanol; or performing cold soaking or thermal reflux extraction on the organic solvent, and extracting with ethyl acetate to obtain a total extract; and repeatedly performing column chromatography on the total extract to obtain the compound. The compound is applied to preparation of an anti-angiogenesis agent, an anti-prolyl endopeptidase agent, an antibacterial agent, an anti-feedant and a flavor: the compound has high antibiotic activity when being applied to a substrate or a group in an amount of 10-1,000muM and being optionally combined with a carrier and/or a medium; the compound has high antifeedant activity when being applied to a substrate or a group in an amount of 0.005-10muM/cm<2> and being optionally combined with a carrier and/or a medium; and the compound has clear flavor and high hair permeability, can be used for improving the hair flavor when used for blending, has the characteristic of unique flavor, is clear and pure, can be used for covering bad flavors of surfactant substrate raw materials, and is safe for a long time.
Owner:KUNMING INST OF BOTANY - CHINESE ACAD OF SCI

Pharmaceutical composition containing, as active ingredient, fusion protein in which tumor-penetrating peptide and Anti-angiogenesis agent are fused, for preventing and treating cancer or angiogenesis-related diseases

The present invention relates to a pharmaceutical composition containing, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-vascular endothelial cell growth factor (anti-VEGF) agent are fused, for treating cancer or angiogenesis-related diseases. More specifically, the present invention relates to a use of the fusion protein for treating cancer or angiogenesis-related diseases, wherein the fusion protein improves the tissue penetrability of an anti-vascular endothelial cell growth factor agent and exerts a cancer targeting effect, thereby producing an excellent angiogenesis inhibiting effect and exhibiting a therapeutic effect on cancer showing resistance or unresponsiveness to the anti-VEGF agent.
Owner:IL DONG PHARMA CO LTD

Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases

The present disclosure provides therapeutic agents for the treatment of age-related macular degeneration (AMD) and other eye disorders. One or more therapeutic agents can be used to treat any stages (including the early, intermediate and advance stages) of AMD, and any phenotypes of AMD, including geographic atrophy (including non-central GA and central GA) and neovascularization (including types 1, 2 and 3 NV). In some embodiments, the one or more therapeutic agents are or include an anti-dyslipidemic agent, an antioxidant, an anti-inflammatory agent, a complement inhibitor, a neuroprotector or an anti-angiogenic agent, or any combination thereof. In certain embodiments, the one or more therapeutic agents are or include an anti-dyslipidemic agent (e.g., an apolipoprotein mimetic or / and a statin). In some embodiments, the one or more therapeutic agents are mixed with, non-covalently associated with or covalently bonded to a cell-penetrating peptide (CPP), encapsulated in CPP-conjugated nanoparticles, micelles or liposomes, or modified (e.g., stapled, prenylated, lipidated or coupled to a small-molecule α-helix mimic) to acquire membrane-translocating ability. In certain embodiments, the one or more therapeutic agents are administered by eye drop.
Owner:MACREGEN INC

Anti-angiogenic adenovirus

The invention relates to a recombinant adenovirus that expresses endostatin, angiostatin, or a combination of endostatin and angiostatin. The invention also relates to method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a combination of (i) a recombinant adenovirus and (ii) an anti-angiogenic agent to treat the cancer inthe subject.
Owner:EPICENTRX

Methods for intradermal delivery of therapeutics agents

The present invention relates to methods and devices for delivering one or more biologically active agents, particularly therapeutic agents, the intradermal compartment of a subject's skin. The present invention provides an improved method of delivery of biologically active agents, such as therapeutic agents, through lymphatic vasculature accessed by intradermal delivery. Therapeutic agents to be delivered in accordance with the present invention include, but are not limited ton antineoplastic agents, chemotherapeutic agents, antibodies, antibiotics, anti-angiogenesis agents, anti-inflammatory agents, and immunotherapeutic agents. Therapeutic agents delivered in accordance with the present invention have improved bioavailability, including improved systemic distribution and improved delivery to particular tissues. Therapeutic agents, delivered in accordance with the methods of the invention have an improved clinical utility and therapeutic efficacy relative to other drug delivery methods, including intraperitoneal, intramuscular and subcutaneous delivery. The methods of the present invention provide benefits and improvements over convention drug delivery methods including dose sparing, increased drug efficacy, reduced side effects, reduced metastatic potential and prolonged survival.
Owner:BECTON DICKINSON & CO

Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors

The invention relates to a combination therapy for the treatment of tumors and tumor metastases comprising administration of receptor tyrosine kinase antagonists / inhibitors, especially ErbB receptor antagonists, more preferably EGF receptor (Her 1) antagonists and anti-angiogenic agents, preferably integrin antagonists, optionally together with agents or therapy forms that have additive or synergistic efficacy when administered together with the combination of antagonists / inhibitors, such as chemotherapeutic agents and or radiation therapy. The therapy can result in a synergistic potential increase of the inhibition effect of each individual therapeutic on tumor cell proliferation, yielding more effective treatment than found by administering an individual component alone.
Owner:THOMSON LICENSING SA

Compositions and Methods for Treatment of Cancer

Resistance of randomly dispersed and oxygen-starved lung tumor cells to chemo- and radiotherapy constitutes the vast majority recurrences and death from lung cancer. We use sickle cells derived from humans with sickle cell anemia to target oxygen-deprived tumor cells that persist and multiply after conventional treatment. Transfused sickle cells selectively occluded tumor microvessels and shut down blood flow to these oxygen-deprived pockets leading to tumor cell death and complete shrinkage of aggressive lung tumors. Combining the sickle cells with a vascular disrupting agents and radiation injure and narrow tumor blood vessels, amplified the scale of sickle cell-induced blood vessel closure and tumor cell killing. The strength of the tumor killing produced by this combination exceeded that of either agent alone or combined with conventional anti-angiogenics, chemotherapy or radiation. Combinatorial sickle cells-Combretastatin treatment thereby constitutes a major advance toward eradicating treatment-resistant tumor cells and reducing the frequency of lung cancer recurrence.
Owner:TERMAN DAVID S
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products